.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 7,482,330

« Back to Dashboard

Details for Patent: 7,482,330

Title:Substituted fused heterocyclic C-glycosides
Abstract: This invention relates to substituted fused heterocyclic C-glycosides, compositions containing them, and methods of using them, for example, for the treatment or prophylaxis of diabetes and Syndrome X.
Inventor(s): Rybczynski; Philip (Branchburg, NJ), Urbanski; Maud (Flemington, NJ), Zhang; Xiaoyan (Belle Mead, NJ)
Assignee: Janssen Pharmaceutica N.V. (Beerse, BE)
Filing Date:Jun 15, 2006
Application Number:11/453,728
Claims:1. A method for treating diabetes in a mammal, said method comprising administering to a mammal in need of treatment an effective amount of a compound of formula (IV): ##STR00017## wherein: one of the dashed lines between NR.sub.1 and X or between X and Y is present, or both are absent; two of V, M, and W are H and the third is ##STR00018## R.sub.1 is H, or C.sub.1-4 alkyl; or, where the dashed line between NR.sup.1 and X is present, R.sub.1 is absent; X is N, C.dbd.O, CH, or C-Q-Z; Y is N-Q-Z or C-Q-Z, where X is N, C.dbd.O, or CH; Y is CH, where X is C-Q-Z; Q=--(CH.sub.2).sub.n-- where n=1 or 2; P=H, C.sub.1-7 acyl, or C.sub.1-6 alkoxycarbonyl; Z is substituted or unsubstituted, and is selected from C.sub.3-7 cycloalkyl, phenyl, a 5- or 6-membered heteroaryl having 1 or 2 heteroatoms independently selected from N, O, and S, a biaryl, a 9- or 10-membered fused bicyclyl, and a fused heterobicyclyl, wherein said fused heterobicyclyl has between 1 and 4 heteroatoms independently selected from N, O, and S; or a pharmaceutically acceptable salt thereof.

2. A The method of claim 1, wherein said diabetes is type II diabetes.

3. A method for lowering serum glucose in a mammal, said method comprising administering to a mammal in need of treatment an effective amount of a compound of formula (IV): ##STR00019## wherein: one of the dashed lines between NR.sub.1 and X or between X and Y is present, or both are absent; two of V, M, and W are H and the third is ##STR00020## R.sub.1 is H, or C.sub.1-4 alkyl; or, where the dashed line between NR.sup.1 and X is present, R.sub.1 is absent; X is N, C.dbd.O, CH, or C-Q-Z; Y is N-Q-Z or C-Q-Z, where X is N, C.dbd.O, or CH; Y is CH, where X is C-Q-Z; Q=--(CH.sub.2).sub.n-- where n=1 or 2; P=H, C.sub.1-7 acyl, or C.sub.1-6 alkoxycarbonyl; Z is substituted or unsubstituted, and is selected from C.sub.3-7 cycloalkyl, phenyl, a 5- or 6- membered heteroaryl having 1 or 2 heteroatoms independently selected from N, O, and S, a biaryl, a 9- or 10-membered fused bicyclyl, and a fused heterobicyclyl, wherein said fused heterobicyclyl has between 1 and 4 heteroatoms independently selected from N, O, and S; or a pharmaceutically acceptable salt thereof.

4. A method for treating diabetes or Syndrome X, or associated symptoms or complications thereof, said method comprising administering to a mammal in need of treatment an effective amount of a compound of formula (IV): ##STR00021## wherein: one of the dashed lines between NR.sub.1 and X or between X and Y is present. or both are absent; two of V, M, and W are H and the third is ##STR00022## R.sub.1 is H, or C.sub.1-4 alkyl; or, where the dashed line between NR.sup.1 and X is present, R.sub.1 is absent; X is N, C.dbd.O, CH, or C-Q-Z; Y is N-Q-Z or C-Q-Z, where X is N, C.dbd.O, or CH; Y is CH, where X is C-Q-Z; Q=--(CH.sub.2).sub.n-- where n=1 or 2; P=H, C.sub.1-7 acyl, or C.sub.1-6 alkoxycarbonyl; Z is substituted or unsubstituted, and is selected from C.sub.3-7 cycloalkyl, phenyl, a 5- or 6-membered heteroaryl having 1 or 2 heteroatoms independently selected from N, O, and S, a biaryl, a 9-or 10-membered fused bicyclyl, and a fused heterobicyclyl, wherein said fused heterobicyclyl has between 1 and 4 heteroatoms independently selected from N, O, and S; or a pharmaceutically acceptable salt thereof.

5. The method of claim 4, wherein said diabetes or Syndrome X, or associated symptoms or complications thereof is selected from the group consisting of IDDM, NIDDM, IGT, IFG, obesity, nephropathy, neuropathy, retinopathy, atherosclerosis, polycystic ovarian syndrome, hypertension, ischemia, stroke, heart disease, irritable bowel disorder, inflammation, and cataracts.

6. A method for reducing the body mass index, body weight, or percentage body fat in a mammal, said method comprising administering to a mammal in need of treatment an effective amount of a compound of formula (IV): ##STR00023## wherein: one of the dashed lines between NR.sub.1 and X or between X and Y is present, or both are absent; two of V, M, and W are H and the third is ##STR00024## R.sub.1 is H, or C.sub.1-4 alkyl; or, where the dashed line between NR.sup.1 and X is present, R.sub.1 is absent; X is N, C.dbd.O, CH, or C-Q-Z; Y is N-Q-Z or C-Q-Z, where X is N, C.dbd.O, or CH; Y is CH, where X is C-Q-Z; Q=--(CH.sub.2).sub.n-- where n=1 or 2; P=H, C.sub.1-7 acyl, or C.sub.1-6 alkoxycarbonyl; Z is substituted or unsubstituted. and is selected from C.sub.3-7 cycloalkyl, phenyl, a 5- or 6-membered heteroaryl having 1 or 2 heteroatoms independently selected from N, O, and S, a biaryl, a 9- or 10-membered fused bicyclyl, and a fused heterobicyclyl, wherein said fused heterobicyclyl has between 1 and 4 heteroatoms independently selected from N, O, and S; or a pharmaceutically acceptable salt thereof.

7. The method of claim 6, wherein said reduction of body mass index is a method for treating obesity or an overweight condition.

8. A method for inhibiting the sodium glucose transporter in a cell, by exposing said cell to a compound of formula (IV): ##STR00025## wherein: one of the dashed lines between NR.sub.1 and X or between X and Y is present. or both are absent: two of V, M, and W are H and the third is ##STR00026## R.sub.1 is H, or C.sub.1-4 alkyl; or, where the dashed line between NR.sup.1 and X is present, R.sub.1 is absent; X is N, C.dbd.O, CH, or C-Q-Z; Y is N-Q-Z or C-Q-Z, where X is N, C.dbd.O, or CH; Y is CH, where X is C-Q-Z; Q=--(CH.sub.2).sub.n-- where n=1 or 2; P=H, C.sub.1-7 acyl, or C.sub.1-6 alkoxycarbonvl; Z is substituted or unsubstituted. and is selected from C.sub.3-7 cycloalkyl, phenyl, a 5- or 6-membered heteroaryl having 1 or 2 heteroatoms independently selected from N, O, and S, a biaryl, a 9- or 10-membered fused bicyclyl, and a fused heterobicyclyl, wherein said fused heterobicyclyl has between 1 and 4 heteroatoms independently selected from N, O, and S; or a metabolite thereof.

9. A method for treating diabetes or Syndrome X, or associated symptoms or complications thereof in a subject in need thereof, comprising a) administering to said subject a jointly effective amount of a compound of formula (IV) ##STR00027## wherein: one of the dashed lines between NR.sub.1 and X or between X and Y is present, or both are absent; two of V, M, and W are H and the third is ##STR00028## R.sub.1 is H, or C.sub.1-4 alkyl; or, where the dashed line between NR.sup.1 and X is present, R.sub.1 is absent; X is N, C.dbd.O, CH, or C-Q-Z; Y is N-Q-Z or C-Q-Z, where X is N, C.dbd.O, or CH; Y is CH, where X is C-Q-Z; Q=--(CH.sub.2).sub.n-- where n=1 or 2; P=H, C.sub.1-7 acyl, or C.sub.1-6 alkoxycarbonyl; Z is substituted or unsubstituted, and is selected from C.sub.3-7 cycloalkyl, phenyl, a 5- or 6-membered heteroaryl having 1 or 2 heteroatoms independently selected from N, O, and S, a biaryl, a 9- or 10-membered fused bicyclyl, and a fused heterobicyclyl, wherein said fused heterobicyclyl has between 1 and 4 heteroatoms independently selected from N, O, and S; or a pharmaceutically acceptable salt, thereof; and b) administering to said subject a jointly effective amount of an RXR agonist, said co-administration being in any order and the combined jointly effective amounts providing the desired therapeutic effect.

10. The method of claim 9, wherein the diabetes or Syndrome X, or associated symptoms or complications thereof is selected from the group consisting of IDDM, NIDDM, IGT, IFG, obesity, nephropathy, neuropathy, retinopathy, atherosclerosis, polycystic ovarian syndrome, hypertension, ischemia, stroke, heart disease, irritable bowel disorder, inflammation, and cataracts.

11. The method of claim 9 wherein the diabetes or Syndrome X, or associated symptoms or complication thereof is IDDM.

12. The method of claim 9, wherein the diabetes or Syndrome X, or associated symptoms or complications thereof is NIDDM.

13. The method of claim 9, wherein the diabetes or Syndrome X, or associated symptoms or complications thereof is IGT or IFG.

14. The method of claim 9, wherein the jointly effective amount of the compound of formula (IV) is from about 10 to 1000 mg.

15. The method of claim 9, wherein the jointly effective amount of the compound of formula (IV) is an amount sufficient to reduce the plasma glucose excretion following a meal.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc